Vivo Capital Fund VIII, L.P.'s Form 4 filing
Bolt Biotherapeutics, Inc.BOLT · filed Nov 22, 2023
- Accession no.
- 0001213900-23-089692
- Filed
- Nov 22, 2023, 6:51 PM ET
- Trade date
- Nov 21, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $3.06K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Capital Fund VIII, L.P.CIK 0001618788 | 10% Owner |
| Vivo Capital VIII, LLCCIK 0001618789 | 10% Owner |
| Vivo Capital Surplus Fund VIII, L.P.CIK 0001628048 | 10% Owner |
| Vivo Panda Fund, L.P.CIK 0001675490 | 10% Owner |
| Vivo Opportunity, LLCCIK 0001728970 | 10% Owner |
| Vivo Panda, LLCCIK 0001843847 | 10% Owner |
| Vivo Opportunity Fund Holdings, L.P.CIK 0001930214 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2023 | Common Stock | SSaleDisposed | −1,707 | $0.90F4 | −$1,536.3 | 1,952,302 | Indirect | |
| Nov 21, 2023 | Common Stock | SSaleDisposed | −236 | $0.90F4 | −$212.4 | 269,587 | Indirect | |
| Nov 21, 2023 | Common Stock | SSaleDisposed | −1,457 | $0.90F4 | −$1,311.3 | 111,662 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
Referenced by the price of 3 transactions in Table I.